Hidradenitis
MONDO:0002260An inflammatory disease involving a pathogenic inflammatory response in the apocrine sweat gland.
Also known as: apocrine sweat gland, apocrine sweat gland inflammation, inflammation of apocrine sweat gland
137 clinical trials for this condition and its sub-types, 21 tagged with Hidradenitis itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Hidradenitis
-
Hidradenitis suppurativa 137 trials
1 sub-type
- Familial acne inversa 0 trials Sub-types →
Most studied deeper sub-types
-
New hope for HS sufferers: Long-Term drug safety trial underway
Disease control OngoingThis study looks at the long-term safety and effectiveness of the drug povorcitinib for people with moderate to severe hidradenitis suppurativa (HS), a painful skin condition. Participants have already completed 54 weeks of treatment in earlier studies. The goal is to monitor sid…
Phase 3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
New pill could ease painful skin condition
Disease control OngoingThis phase 3 study tests an oral drug called remibrutinib in 565 people with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition causing painful lumps. Participants receive one of two doses of remibrutinib or a placebo for 68 weeks. The main goal is to see …
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
New pill could ease painful skin condition
Disease control OngoingThis phase 3 trial tests an oral drug called remibrutinib in 588 people with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition causing painful lumps. The study compares two doses of the drug against a placebo over 68 weeks. The main goal is to see if the …
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
New antibody drug aims to calm painful skin condition
Disease control OngoingThis Phase 2 trial tests tibulizumab, a dual-action antibody, in 225 adults with hidradenitis suppurativa (HS), a chronic skin condition causing painful abscesses. Participants first receive either the drug or a placebo for 16 weeks, then everyone gets the drug for another 16 wee…
Phase 2 • Sponsor: Zura Bio Inc • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New hope for HS sufferers: Long-Term drug trial expands
Disease control By invitation onlyThis study looks at the long-term safety and effectiveness of a drug called sonelokimab for people with moderate to severe hidradenitis suppurativa (HS), a painful skin condition. About 835 adults and teens who completed an earlier sonelokimab study will receive the drug for an e…
Phase 3 • Sponsor: MoonLake Immunotherapeutics AG • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New drug trial aims to help teens with painful skin condition
Disease control OngoingThis study tests a drug called sonelokimab in 35 teenagers aged 12 to 17 with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition that causes painful lumps. The main goals are to see how the drug moves through the body and whether it is safe. Researchers wi…
Phase 3 • Sponsor: MoonLake Immunotherapeutics AG • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC